Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 12 September 2017


ZOSTAVAX is indicated for prevention of herpes zoster (“zoster” or shingles) and herpes zoster-related post-herpetic neuralgia (PHN).

ZOSTAVAX is indicated for immunization of individuals 50 years of age or older.

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone

Fabry Disease

Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A

Visit Fabry Disease

Related Content

More information

Category Value
Agency product number EMEA/H/C/000674
Orphan designation No
Date First Approved 19-05-2006
Type Medicinal product subject to medical prescription
Marketing authorisation holder MSD VACCINS